

ACCELERATE HEALING FOR PEOPLE STRUGGLING WITH ADDICTION

Addiction continues to ravage our community, destroying lives and families. Despite reaching crisis levels, effective treatments remain limited. However, psychedelics combined with behavioral interventions provide a new opportunity to change the way we approach treatment — and the results are very promising. With your caring support, we can create a new program to accelerate novel therapeutics in addiction psychiatry that could have a huge impact on public health.

A POWERFUL NEW TREATMENT

Within the field of addiction research, new evidence points to the effectiveness of psychedelic compounds when combined with behavioral interventions for treating addictions, including alcohol, opioid, and tobacco use disorders. Psychedelics when paired thoughtfully with therapy seem to change the way people see themselves, their behaviors, histories and futures, in a way that increases internal motivation.

We hope to further investigate this potentially powerful treatment option with the creation of a new program within the UW Department of Psychiatry and Behavioral Sciences.

This program will advance research into this emerging treatment approach, generating data, identifying best practices and perhaps one day helping to set national standards for how to best use psychedelics and other emerging therapies to treat substance use disorders. Together, we can explore a new method of care that can make a profound difference in people's lives and open the door to massive changes in how we treat addiction.

NO BETTER PLACE OR TIME

UW Medicine is a leader in research and clinical care for those struggling with addiction. The new program — with a long-term goal of becoming a center — will bring together experts with decades of experience across multiple disciplines around three pillars:

BASIC RESEARCH

The program will engage key investigators in psychiatry, neuroscience, psychology, anesthesiology, toxicology and pharmacology to leverage shared resources and improve our understanding of how to best use substances like psilocybin, ketamine, MDMA and other compounds safely in a clinical application.



NATHAN SACKETT

An addiction psychiatrist at UW Medicine, Nathan Sackett, MD, MS, RN, is leading the creation of the program for new therapies in addiction psychiatry.

Dr. Sackett is the first recipient of the Clinician Scientist Transition Award, which he is leveraging to explore novel therapeutics, such as the use of psychedelics to treat substance use disorders.

CLINICAL TRIALS

We will work to develop a range of clinical trials to identify the best pairings of novel compounds and behavioral interventions to treat a variety of substance use disorders.

EDUCATION AND TRAINING

As the use of psychedelics and other novel compounds becomes more prevalent, we aim to develop a standardized training program for clinicians and therapists who want to incorporate the safe and effective use of these treatments into their practices.

With addiction rates soaring, there is an urgent need for innovative and effective treatment options for those impacted by substance use disorders. There are already promising studies suggesting the efficacy of psychedelics when paired with therapy, but more data is needed. This new program seeks to accelerate the process so more people can get the help they need.

A PHILANTHROPIC OPPORTUNITY TO DRIVE INNOVATION IN ADDICTION TREATMENT

Together, we can create a first-of-its-kind program in the Pacific Northwest to develop new therapies for addiction using psychedelics. Your generous commitment can advance promising new treatment options for substance use disorders in the following ways:

Help launch the program with a foundational gift of \$1 million. A bold vision requires bold philanthropic support. A gift of \$1 million would cover the program's first five years of operation and would fund the needed infrastructure to coordinate complex research across multiple departments.

Ensure strong leadership by creating an endowed professorship with a gift of \$500,000. In addition to establishing a legacy, creating an endowed professorship helps recruit, retain and support outstanding faculty leaders.

Help establish a model for clinical trials with a gift of \$250,000. Your investment could launch the program's first identified clinical trial — ketamine for tobacco use disorder — creating a foundation for future trials in alcohol, opioid and other substance use disorders.

Support education and training programs with a gift of \$200,000. A gift of this amount would allow us to develop a consultation line that could provide advice to community providers, therapists and caregivers on the use of psychedelics to treat addictions.

Invest in faculty leadership by funding protected time with a gift of \$25,000. A current-use gift of \$25,000 would provide essential funding for leaders to protect their time to develop this new program, with the goal of eventually becoming a center.

JOIN US

Addiction is a complex health issue that requires experts from many departments and disciplines working together to identify effective solutions. The creation of a program for novel therapeutics in addiction psychiatry could provide those solutions and give people struggling with substance use disorders and their families the hope and options they urgently need.

If you would like to learn more, please contact **Nathan Sackett, MD, MS, RN, at nathan9@uw.edu**. To learn more about philanthropic opportunities, please contact **Katherine Cardinal, senior director for philanthropy, at 206.650.4503 or cardinal@uw.edu**. Thank you for your interest in our work.